Multiple sclerosis: relationship between locus of control and quality of life in persons with low versus high disability

por Bijoux Leist, Judith, Leist, Thomas P.
Publicado 2022

Involvement of β-chemokines in the development of inflammatory demyelination

por Banisor, Ileana, Leist, Thomas P, Kalman, Bernadette
Publicado 2005

T cell responses to COVID-19 infection and vaccination in patients with multiple sclerosis receiving disease-modifying therapy

por Reder, Anthony T, Stuve, Olaf, Tankou, Stephanie K, Leist, Thomas P
Publicado 2022

Cladribine tablets added to IFN-β in active relapsing MS: The ONWARD study

por Montalban, Xavier, Leist, Thomas P., Cohen, Bruce A., Moses, Harold, Campbell, Jackie, Hicking, Christine, Dangond, Fernando
Publicado 2018

The Development of Cladribine Tablets for the Treatment of Multiple Sclerosis: A Comprehensive Review

por Rammohan, Kottil, Coyle, Patricia K., Sylvester, Elke, Galazka, Andrew, Dangond, Fernando, Grosso, Megan, Leist, Thomas P.
Publicado 2020

N-acetyl Cysteine Administration Is Associated With Increased Cerebral Glucose Metabolism in Patients With Multiple Sclerosis: An Exploratory Study

por Monti, Daniel A., Zabrecky, George, Leist, Thomas P., Wintering, Nancy, Bazzan, Anthony J., Zhan, Tingting, Newberg, Andrew B.
Publicado 2020

Treatment-emergent adverse events occurring early in the treatment course of cladribine tablets in two phase 3 trials in multiple sclerosis

por Oh, Jiwon, Walker, Bryan, Giovannoni, Gavin, Jack, Dominic, Dangond, Fernando, Nolting, Axel, Aldridge, Julie, Lebson, Lori A, Leist, Thomas P
Publicado 2021

Integrated Lymphopenia Analysis in Younger and Older Patients With Multiple Sclerosis Treated With Cladribine Tablets

por Giovannoni, Gavin, Coyle, Patricia K., Vermersch, Patrick, Walker, Bryan, Aldridge, Julie, Nolting, Axel, Galazka, Andrew, Lemieux, Caroline, Leist, Thomas P.
Publicado 2021

The efficacy of cladribine tablets in CIS patients retrospectively assigned the diagnosis of MS using modern criteria: Results from the ORACLE-MS study

por Freedman, Mark S, Leist, Thomas P, Comi, Giancarlo, Cree, Bruce AC, Coyle, Patricia K, Hartung, Hans-Peter, Vermersch, Patrick, Damian, Doris, Dangond, Fernando
Publicado 2017

Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trial

por Weinstock-Guttman, Bianca, Bermel, Robert, Cutter, Gary, Freedman, Mark S, Leist, Thomas P, Ma, Xiaoye, Kile, Deidre, Musch, Bruno, Reder, Anthony T, Wolinsky, Jerry S
Publicado 2021

Early MRI outcomes in participants with a first clinical demyelinating event at risk of multiple sclerosis in the ORACLE-MS study

por Freedman, Mark S, Coyle, Patricia K, Comi, Giancarlo, L Scarberry, Susan, Damian, Doris, Hyvert, Yann, Dangond, Fernando, Galazka, Andrew, Jack, Dominic, Lebson, Lori A, Leist, Thomas P
Publicado 2021

N-acetyl cysteine administration affects cerebral blood flow as measured by arterial spin labeling MRI in patients with multiple sclerosis

por Shahrampour, Shiva, Heholt, Justin, Wang, Andrew, Vedaei, Faezeh, Mohamed, Feroze B., Alizadeh, Mahdi, Wang, Ze, Zabrecky, George, Wintering, Nancy, Bazzan, Anthony J., Leist, Thomas P., Monti, Daniel A., Newberg, Andrew B.
Publicado 2021